Close Menu

NEW YORK – Swiss startup 4D Lifetec and epigenetic diagnostic firm VolitionRx said Tuesday that they have partnered to evaluate whether combining their respective assay technologies can better identify individuals with early-stage cancer.

Under the agreement the companies intend to conduct a clinical validation trial using their platforms in a set of lung cancer clinical samples.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.